Objective: To compare the effect of preconception initiation of zidovudine, lamivudine, nevirapine (ZDV/3TC/NVP) versus tenofovir, emtricitabine, efavirenz (TDF/FTC/ EFV) on adverse birth outcomes.
Introduction
Maternal antiretroviral therapy (ART) in pregnancy has been shown to increase the risk of adverse birth outcomes, including stillbirth, preterm delivery, and small-for-gestational-age (SGA) infants in randomized clinical trials [1, 2] . Recent findings suggest that the risk varies across drugs or regimens, and that outcomes may be worse among infants exposed to ART from conception [2] [3] [4] [5] [6] . Ideally, a randomized trial would assign women to one of several commonly prescribed ART regimens before conception and compare birth outcomes between groups, but such a trial is not feasible. Therefore, observational data need to be used to emulate such a trial [7] [8] [9] .
Our previous analyses of observational data from Botswana found an increased risk of adverse birth outcomes among infants exposed to ART from conception [4, 10] , and suggested that exposure to zidovudine (ZDV), lamivudine (3TC), and nevirapine (NVP) in combination had significantly higher risk for all adverse birth outcomes than exposure to tenofovir (TDF), emtricitabine (FTC), and efavirenz (EFV) in combination [6] . However, we cannot exclude the possibility that these results were influenced by residual confounding: women initiated these regimens at different CD4 þ cell count thresholds, those on NVP-based ART had received it for a longer duration in contemporaneous comparisons, and the risk for adverse birth outcomes may have changed over time. Also, our previous analyses included only a subset of the surveillance data sets that are currently available from Botswana.
Here we describe two alternative approaches to emulate a (hypothetical) target trial of ZDV/3TC/NVP versus TDF/FTC/EFV: an historical comparison and a contemporaneous comparison. Each of these approaches addresses a critical component of confounding in the emulation of the target trial. The historical comparison is less susceptible to bias from differences between groups of women initiating each treatment, but susceptible to time trends in prescription patterns and adverse birth outcomes. The contemporaneous comparison is immune to bias from time trends, but is susceptible to bias from differences between groups of women. Because our analyses combine all surveillance data from Botswana, our estimates are more precise than those previously published. [4] . The surveillance hospitals are geographically diverse and capture $45% of births nationwide. In Botswana, approximately 95% of women deliver in a hospital.
Methods

Data sources
Our data are restricted to approximately 80 000 women who delivered at at least 24-week gestation at these hospitals, of which approximately 20 000 were HIVinfected. We collected information on HIV status, date of HIV diagnosis, ART start date, ART regimen, medical and obstetric history, and birth outcomes as documented in the obstetric cards. The estimated gestational age was documented by nurses at the time of delivery, generally using the last menstrual period and confirmed by ultrasound ($10%) when available. If the last menstrual period date was unknown or suspected to be incorrect, fundal height measurements were occasionally used by the midwives to estimate gestational age.
In Botswana, the recommended first-line three-drug ART regimen changed from ZDV/3TC/NVP to TDF/ FTC/EFV in 2012 [11] . At this time, the recommended threshold at which ART initiation was initially offered to nonpregnant women also changed from CD4 þ cell count 250 cells/ml or less to 350 cells/ml or less.
The protocol of the target trial
The protocol of our target trial to compare the effect of initiating ART regimens preconception on birth outcomes is as follows:
Eligibility criteria
The target trial includes nonpregnant women living in Botswana in or after 2004 who were diagnosed with HIV within the previous 3 years.
Treatment strategies
Initiation of either TDF/FTC/EFV or ZDV/3TC/NVP. Ideally, the hypothetical study intervention would also include conception between 6 months (to allow sufficient time for CD4 þ cell count reconstitution) and 5 years after randomization (ART initiation) and a birth outcome at at least 24 weeks at a surveillance hospital site in Botswana.
Treatment assignment
Eligible women are randomly assigned to initiate either TDF/FTC/EFV or ZDV/3TC/NVP.
Outcomes
The primary outcomes of interest include stillbirth, defined as fetal death at least 24-week gestation with an Apgar score of 0,0,0; preterm delivery (delivery <37-week gestation); very preterm delivery (delivery <32-week gestation); SGA (<10th percentile of birth weight using WHO norms); and very SGA (<3rd percentile of birth weight using WHO norms) [12, 13] . The combined endpoint of any adverse birth outcome includes stillbirth, preterm delivery, or SGA and the combined endpoint of any severe adverse birth outcome includes stillbirth, very preterm delivery, or very SGA.
Follow-up period Women are followed from ART initiation (randomization) until discharge from the maternity ward.
Causal contrast of interest
To compare the two treatment strategies, we estimate the modified intention-to-treat effect of initiating ZDV/ 3TC/NVP versus TDF/FTC/EFV on each of the outcomes of interest, that is, the effect among those who became pregnant 6 months to 5 years after randomization.
Analysis plan
For each birth outcome, we fit a log-binomial regression model to estimate the risk ratio of the birth outcome of interest comparing ZDV/3TC/NVP with TDF/FTC/ EFV. When the log-binomial model fails to converge, we instead fit a Poisson regression model with robust variance [14] .
Sensitivity analyses for selection bias
The target trial is susceptible to selection bias because individuals are excluded from the analysis based on events that occur after baseline (randomization). Women who do not become pregnant, become pregnant but not between 6 months and 5 years of ART initiation, become pregnant but miscarry or deliver less than 24-week gestation, do not have a birth outcome at at least 24-week gestation at a hospital site in Botswana, deliver twins or triplets, or have missing data for the outcome of interest are excluded from our analysis. In sensitivity analyses, we vary the time from ART initiation to pregnancy window (e.g., allowing a pregnancy date between 0 days and 12 years after ART initiation in the most extreme case), including the first birth among women who deliver twins or triplets, and using inverse probability of censoring weights to adjust for potential selection bias due to incomplete data on birth outcomes.
Emulation of the target trial using observational data We emulated the target trial by using the combined data set of our birth outcomes surveillance studies.
Eligibility criteria, treatment strategies, follow-up, outcome, causal contrasts Same as in the target trial. The historical comparison is less likely to be affected by confounding by indication as the analysis compares generally similar women, but may be affected by temporal trends in adverse birth outcomes. The contemporaneous comparison is less likely to be biased due to time trends in adverse birth outcomes but may be biased if there is confounding by indication that is not successfully adjusted for in the analysis stage, for example, if a clinician prescribes a nonstandard regimen to an individual for reasons not collected in the data. The primary difference between women offered ART in different treatment eras was a change in the CD4 þ cell count threshold at which ART was initially offered to nonpregnant women: from CD4 þ cell count 200 cells/ml or less to 250 cells/ml or less in 2008 and from CD4 þ cell count 250 cells/ml or less to 350 cells/ml or less in 2012 [11] .
Analysis plan
The analysis was the same as in the target trial except that we included the following prognostic factors in our models, which are also predictors of ART regimen [4, 6, 10] : year of ART initiation (2009) (2010) (2011) (2012) (2013) ; contemporaneous comparison only), time from HIV diagnosis to ART initiation (1 year or less, more than 1 year), age at ART initiation (<25, 25-30, !30 years, unknown), marital status (married, unmarried or unknown), occupation (salaried, unsalaried or unknown), education (none or primary, more than primary, unknown), and parity (0, 1, or more, unknown).
To determine whether there may have been time trends in adverse birth outcomes in Botswana during the timeperiod of interest, we used data from the HIV-negative women enrolled in the birth outcomes surveillance study and calculated the risk of each adverse birth outcome by calendar year.
Sensitivity analyses
Like the target trial, our emulation is susceptible to selection bias because individuals are excluded from the analysis based on events that occur after baseline (randomization). We performed the same sensitivity analyses for selection bias as in the target trial.
We performed several additional sensitivity analyses for confounding. To explore whether our results could be explained by variations in CD4 þ cell count across the two treatment groups, we restricted the analysis to the subset of individuals with reconstituted CD4 þ cell counts (!200 cells/ml) during pregnancy, and to a limited treatment era with the same CD4 þ cell count threshold for initiating ART (!250 cells/ml) (2008) (2009) (2010) (2011) . Other sensitivity analyses are described in Appendix 1, http:// links.lww.com/QAD/B178.
Due to concerns about measurement error in the last menstrual period documented at the first antenatal care visit, the date of conception was estimated using the reported gestational age at birth and the recorded delivery date in the primary analysis and using the documented last menstrual period in a sensitivity analysis.
Statistical analyses were performed using SAS, version 9.3 (SAS Institute, Cary, North Carolina, USA). 
Ethical approval
Results
Historical comparison
Of 21 640 HIV-positive women who delivered at one of the selected hospitals at at least 24-week gestation, 4850 (22%) started ARTwithin 3 years of HIV diagnosis while nonpregnant. There were 1249 women who started TDF/FTC/EFV in 2012-2015 and 1594 women who started ZDV/3TC/NVP in 2004-2011. Of these, 1108 women who started TDF/FTC/EFV and 637 women who started ZDV/3TC/NVP had a pregnancy date between 6 months and 5 years after starting ART, a birth outcome at at least 24 weeks, and delivered a singleton birth (Fig. 1, Table 1 ). Compared with women who initiated ZDV/3TC/NVP, women who initiated TDF/ FTC/EFV were more likely to have attained a higher level of education, be younger than 25 years of age and be nulliparous. The median number of days from HIV diagnosis to ART initiation was greater among those who initiated ZDV/3TC/NVP compared with those who initiated TDF/FTC/EFV (Table 2) . Among women with data on CD4 þ cell count in pregnancy (25%), the median [interquartile range (IQR)] first CD4 þ cell count during pregnancy was 487 (374, 618) cells/ml for women who initiated TDF/FTC/EFV and 408 (282, 533) for women who initiated ZDV/3TC/NVP cells/ml. Information on birth outcomes was recorded in almost all women included in the study (100% for stillbirth, 98-100% for preterm delivery depending on how date of conception was defined, and 98% for SGA). Of the women included in the analysis, 67 had a stillbirth (3.8%),
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AIDS (Table 3) .
None of the sensitivity analyses yielded appreciably different results (Appendix Tables 1 and 2 , http:// links.lww.com/QAD/B178).
Contemporaneous comparison
There were 1186 women who started TDF/FTC/EFV and 491 women who started ZDV/3TC/NVP between 2009 and 2013. Of these, 1052 women who started TDF/FTC/EFV and 298 women who started ZDV/ 3TC/NVP had a pregnancy date between 6 months and 5 years after starting ART and delivered a singleton birth at at least 24 weeks (Fig. 1 , Table 1 ). The baseline characteristics of women in the contemporaneous comparison were similar to those of women in the historical comparison (Table 2) . Compared with women who initiated ZDV/3TC/NVP, women who initiated TDF/FTC/EFV were more likely to have initiated ART in the later calendar years of this restricted time period. Among women with data on CD4 þ cell count in pregnancy (23%), the median (IQR) first CD4 þ cell count during pregnancy was 480 (368, 613) cells/ml for women who initiated TDF/FTC/EFV and 448 (367, 597) cells/ml for women who initiated ZDV/3TC/NVP.
The risks of adverse birth outcomes were similar in the contemporaneous comparison and the historical comparison. The adjusted risk ratios were slightly smaller for very preterm delivery and very SGA in the contemporaneous comparison compared with the historical comparison, but were otherwise very similar (Table 3) . ART, antiretroviral therapy; TDF/FTC/EFV, tenofovir, emtricitabine, efavirenz; ZDV/3TC/NVP, zidovudine, lamivudine, nevirapine.
HIV-negative women
To evaluate historical trends in birth outcome, we also evaluated HIV-negative women in each study era. Table 4) . These patterns were similar when restricting to the five study sites included in all surveillance years.
Discussion
We combined two large observational data sets from Botswana to emulate a randomized trial comparing adverse birth outcomes among women initiating ZDV/ 3TC/NVP and TDF/FTC/EFV prior to conception. Our findings suggest that preconception initiation of ZDV/3TC/NVP compared with TDF/FTC/EFV increases the risk of all adverse and severe adverse birth outcomes. The risk of stillbirth after initiating ZDV/ 3TC/NVP was approximately three times the risk of stillbirth after initiating TDF/FTC/EFV, and the risk of any severe adverse birth outcome after initiating ZDV/3TC/NVP was approximately two times the risk of any severe adverse birth outcome after initiating 118 AIDS 2018, Vol 32 No 1 Adjusted for years from HIV diagnosis to ART initiation, age, occupation, education, and parity only. TDF/FTC/EFV. To address competing sources of bias, we performed historical and contemporaneous comparisons, and our results were similar across all analyses and with those found in a previous study using data from 2014 to 2016 [6] .
In the absence of large randomized trials to study drug safety, observational data can be used to emulate a target trial. Outlining the protocol of the target trial and its emulation using observational data makes key components of the study explicit, avoids common biases in observational data analyses, and facilitates a discussion about the limitations of the data. By evaluating how successfully we can emulate each component of the target trial in our observational data, we can attempt to explain how our results may differ from those that would be observed if the target trial could be performed as outlined in the protocol.
A key challenge in emulating a target trial is adjusting for confounding. In this article, we described two alternative approaches to emulate the randomization of a target trial when confounding adjustment is questionable. The historical comparison compares individuals who initiated the treatment strategy that was recommended by the guidelines at the time they initiated treatment and the contemporaneous comparison compares individuals who initiated the two treatments during the same time period. Each approach isolates a potential source of confounding: differences between individuals initiating one treatment compared with another and time-trends in the outcome of interest.
The validity of the historical comparison relies on the assumption that women who initiated TDF/FTC/EFV while it was the recommended treatment regimen (2012) (2013) (2014) (2015) and women who initiated ZDV/3TC/ NVP while it was the recommended treatment regimen (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) are comparable. This assumption may not hold if characteristics of women starting ART changed over calendar time. This is unlikely as the demographics of women included in these comparisons were generally similar by treatment era (Table 2) , and small differences between age, time from HIV diagnosis to ART initiation, education, and parity were adjusted for in the analysis. However, as ART was offered at lower CD4 þ cell count thresholds earlier in the epidemic, it is likely that women initiating ART in 2004-2011 had lower nadir CD4 þ cell counts compared with women initiating ART in 2012-2015. Although information on nadir CD4 þ cell count was not available in our study, we limited potential confounding by disease severity by restricting the analysis to women who became pregnant at least 6 months after initiating ART (to allow sufficient time for CD4 þ cell count reconstitution) in our primary analysis; restricting our analysis to the subset of individuals with reconstituted CD4 þ cell counts (!200 cells/ml) during pregnancy in sensitivity analyses; and performing a sensitivity analysis restricted to the time period when ARTwas started at the same CD4 þ cell count threshold. Lastly, the historical comparison may also be affected by improvements in birth outcomes in Botswana over time, which appeared to be the case among HIV-negative women evaluated in our parallel analysis. However, these relative differences in outcomes over time were insufficient to explain the much larger differences observed by ART exposure groups.
The validity of the contemporaneous comparison relies on the assumption that restricting the analysis to 2009-2013 eliminated confounding by calendar year. This may not be the case if prescription patterns changed and there were time trends in adverse birth outcomes within this period. The contemporaneous comparison was designed explicitly to reduce confounding by calendar time, but the validity of its results also depends on the assumption of no residual confounding in general.
In both comparisons, measurement error for preterm delivery and SGA was possible as gestational age was calculated using the recorded last menstrual period date and maternity nurse assessment, but it is unlikely that this error would be differential with respect to ART regimen (the error may affect absolute risk estimates but likely would not affect relative risk estimates). Finally, selection bias in our study was possible as individuals were excluded from the analysis based on events that occurred after baseline. Our results did not materially change in sensitivity analyses designed to adjust for this potential selection bias, but we were not able to adjust for potential selection bias due to the exclusion of women who did not become pregnant or did not have a birth outcome at at least 24-week gestation at one of the eight hospital sites. To our knowledge, there is no biological rationale or evidence in the literature for an association between these two ART regimens and the ability to conceive.
The mechanisms by which ZDV/3TC/NVP may increase the risk of adverse birth outcomes compared with TDF/FTC/EFV have been discussed previously [6] . One potential explanation is that ART could affect fetal growth through differential effects on the health of the placenta [15] , which is supported by the larger risk ratio comparing the two regimens for SGA than for preterm birth. Our findings differ somewhat from the PROMISE trial [2] , which found an increased risk of severe adverse birth outcomes after initiation of ritonavir-boosted lopinavir paired with TDF/FTC versus ZDV/3TC among women with CD4 þ cell count more than 350 cells/ml randomized after 14 weeks of pregnancy. However, this discrepancy could be explained by different baseline CD4 þ cell counts, preconception versus postconception treatment initiation, or a potential interaction between TDF and the boosted lopinavir used in the PROMISE trial.
Our analysis included women in Botswana who initiated ART according to CD4 þ -based initiation guidelines.
Although sensitivity analyses by CD4 þ count thresholds yielded similar results, the effect estimates we observed may differ from the present era in which ART is initiated earlier. In addition, our study design required 6 months on ART before conception, possibly excluding women with the lowest CD4 þ cell counts.
The proposed alternative approaches to emulate the randomized treatment assignment of a target trial may be useful for other studies of drug safety in pregnancy, and for the field of HIV in general as treatment options change over time in developing world settings in which the medical standard of care may be improving. For example, when a new drug therapy becomes available but the comparative safety of the standard drug versus the new drug remains unknown, historical and contemporaneous comparisons may be useful to isolate key sources of confounding.
In summary, we conducted two emulations of a target trial to compare the safety of preconception initiation of ZDV/3TC/NVP compared with TDF/FTC/EFV on adverse birth outcomes in Botswana. These emulations confirmed previous findings that preconception initiation of ZDV/3TC/NVP compared with TDF/FTC/EFV results in an increased risk of adverse and severe adverse birth outcomes. This methodology addresses the concern that previous results could be partly explained by unadjusted confounding, and adds to the growing body of literature suggesting a harmful effect of in-utero exposure to ZDV/3TC/NVP.
